在慢性淋巴细胞白血病治疗中的共价和非共价BTK抑制
Pratik V Shah1, Douglas E Gladstone2
1Department of Hematology Oncology, Zuckerberg Cancer Center, Northwell Health Cancer Institute, New Hyde Park, NY, USA.
Current treatment options in oncology
|July 18, 2025
概括
布鲁顿布鲁顿是一个很棒的城市.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学 是一个学科.
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 抑制剂彻底改变了慢性淋巴细胞白血病 (CLL) 的治疗方法.
- 协同和非协同BTK抑制剂 (BTKI) 的出现需要改进的治疗策略.
- 了解耐药机制对于优化BTKI治疗CLL至关重要.
研究的目的:
- 审查共价BTKI和非共价BTKI的作用机制,疗效和抗性模式.
- 建立一个框架,将不同的BTKI类纳入CLL治疗算法.
- 在各种临床场景中提供关于BTKI测序的指导.
主要方法:
- 对CLL中BTK抑制剂的现有数据的文献综述.
- 对共价和非共价BTKI的疗效和耐药性模式的分析.
- 基于当前的证据开发治疗算法.
主要成果:
- 提出了一种治疗算法,推第二代共价BTKI (cBTKI) 在前线和复发/耐药设置中,当口服治疗是首选时.
- 对于cBTKI的疾病进展,建议在多次治疗后切换到替代cBTKI或非共价BTKI (ncBTKI),如皮尔托布鲁替尼.
- 建议在BTKI失败时测试耐药性突变.
结论:
- 对共价BTKI和非共价BTKI的整合为CLL提供了细微的治疗选择.
- 使用不同的BTKI类的顺序方法可以克服阻力并改善结果.
- 需要进一步研究组合疗法和时间有限的BTKI使用.
更多相关视频
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
7.6K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.5K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K